Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$21.71 -0.1%	$17.87	$13.40 ▼ $25.23	$3.63B	0.65	1.94 million shs	1.11 million shs
CMTA Clementia Pharmaceuticals	$26.35	$26.35	$8.10 ▼ $26.73	$1.00B	0.64	145,059 shs	716,706 shs
CYTK Cytokinetics	$34.38 +3.6%	$34.83	$29.31 ▼ $61.38	$4.11B	0.59	1.55 million shs	1.58 million shs
SRPT Sarepta Therapeutics	$36.18 -3.0%	$46.51	$34.10 ▼ $173.25	$3.56B	0.61	1.81 million shs	3.23 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-2.51%	+1.87%	+26.40%	+24.23%	+41.44%
CMTA Clementia Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
CYTK Cytokinetics	+0.27%	+3.49%	+8.46%	-25.16%	-38.56%
SRPT Sarepta Therapeutics	-1.32%	-4.85%	+3.07%	-61.61%	-68.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.2501 of 5 stars	3.3	1.0	0.0	0.0	3.3	4.2	1.3
CMTA Clementia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	4.3629 of 5 stars	4.5	3.0	0.0	4.6	2.5	0.8	0.0
SRPT Sarepta Therapeutics	4.7609 of 5 stars	4.4	2.0	0.0	4.2	3.1	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.69	Moderate Buy	$26.79	23.38% Upside
CMTA Clementia Pharmaceuticals	0.00	N/A	N/A	N/A
CYTK Cytokinetics	2.93	Moderate Buy	$70.92	106.29% Upside
SRPT Sarepta Therapeutics	2.87	Moderate Buy	$122.61	238.89% Upside

Current Analyst Ratings Breakdown

Latest CMTA, CYTK, SRPT, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	CYTK Cytokinetics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$71.00 ➝ $53.00
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/6/2025	SRPT Sarepta Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$80.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
5/29/2025	CYTK Cytokinetics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$103.00 ➝ $84.00
5/22/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$40.00 ➝ $40.00
5/21/2025	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00 ➝ $35.00
5/20/2025	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $24.00
5/20/2025	SRPT Sarepta Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$169.00 ➝ $84.00
5/19/2025	ACAD ACADIA Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$28.00 ➝ $31.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$996.28M	3.65	N/A	N/A	$2.63 per share	8.25
CMTA Clementia Pharmaceuticals	N/A	N/A	N/A	N/A	$5.18 per share	N/A
CYTK Cytokinetics	$19.22M	213.65	N/A	N/A	($3.94) per share	-8.73
SRPT Sarepta Therapeutics	$2.23B	1.59	N/A	N/A	$9.19 per share	3.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	-$61.29M	$1.37	27.83	28.57	N/A	13.83%	25.83%	14.71%	8/5/2025 (Estimated)
CMTA Clementia Pharmaceuticals	-$58.13M	-$7.93	N/A	N/A	N/A	N/A	-44.73%	-41.66%	N/A
CYTK Cytokinetics	-$526.24M	-$5.29	N/A	N/A	N/A	-17,906.25%	N/A	-50.21%	8/6/2025 (Estimated)
SRPT Sarepta Therapeutics	-$535.98M	-$2.69	28.94	3.31	N/A	7.43%	11.00%	3.35%	8/6/2025 (Estimated)

Latest CMTA, CYTK, SRPT, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/6/2025	Q1 2025	CYTK Cytokinetics	-$1.41	-$1.36	+$0.05	-$1.36	$2.77 million	$1.60 million
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CMTA Clementia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.29	2.11
CMTA Clementia Pharmaceuticals	N/A	14.03	14.03
CYTK Cytokinetics	5.93	9.28	9.28
SRPT Sarepta Therapeutics	0.93	3.84	3.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
CMTA Clementia Pharmaceuticals	78.72%
CYTK Cytokinetics	N/A
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
CMTA Clementia Pharmaceuticals	N/A
CYTK Cytokinetics	2.70%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	119.30 million	Optionable
CMTA Clementia Pharmaceuticals	30	38.06 million	N/A	Not Optionable
CYTK Cytokinetics	250	119.43 million	114.00 million	Optionable
SRPT Sarepta Therapeutics	840	98.28 million	88.17 million	Optionable

CMTA, CYTK, SRPT, and ACAD Headlines

Recent News About These Companies

Tobam Has $2.41 Million Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

June 13 at 6:23 AM | marketbeat.com

Assenagon Asset Management S.A. Raises Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

June 13 at 4:35 AM | marketbeat.com

GAMMA Investing LLC Purchases 39,991 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

June 13 at 3:17 AM | marketbeat.com

Sarepta Therapeutics’ (SRPT) Rating Downgrade Dents Share Price

June 11 at 4:06 AM | yahoo.com

1 Unprofitable Stock for Long-Term Investors and 2 to Ignore

June 10 at 7:33 AM | uk.finance.yahoo.com

Sarepta Therapeutics (NASDAQ:SRPT) Trading Down 6.1% - Should You Sell?

June 9, 2025 | marketbeat.com

Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to Sector Outperform at Scotiabank

June 9, 2025 | americanbankingnews.com

BMO Capital Remains a Buy on Sarepta Therapeutics (SRPT)

June 8, 2025 | theglobeandmail.com

Sarepta Therapeutics (NasdaqGS:SRPT) Gains 19% Over Past Month Following Japan Approval

June 8, 2025 | finance.yahoo.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 8% - Should You Buy?

June 8, 2025 | americanbankingnews.com

July 25th Options Now Available For Sarepta Therapeutics (SRPT)

June 7, 2025 | nasdaq.com

Sarepta Therapeutics’ gene therapy to treat limb girdle muscular dystrophy type 2E/R4 gets US FDA platform technology designation

June 7, 2025 | pharmabiz.com

Sarepta upgraded at Scotiabank on attractive risk reward setup

June 7, 2025 | msn.com

Scotiabank Upgrades Sarepta Therapeutics (SRPT)

June 7, 2025 | msn.com

Sarepta Therapeutics Approves Amendments at Annual Meeting

June 6, 2025 | tipranks.com

Sarepta Therapeutics (NASDAQ:SRPT) Trading Up 8% - Here's Why

June 6, 2025 | marketbeat.com

Sarepta Therapeutics (SRPT) Upgraded by Scotiabank with Sector Outperform Rating | SRPT Stock News

June 6, 2025 | gurufocus.com

Scotiabank Upgrades Sarepta Therapeutics (NASDAQ:SRPT) to "Sector Outperform"

June 6, 2025 | marketbeat.com

FDA grants Platform designation for Sarepta’s SRP-9003

June 6, 2025 | thepharmaletter.com

Sarepta Wins FDA’s Platform Technology Designation, Marking ‘Critical Shift’ in Gene Therapy Development

June 6, 2025 | biospace.com

The FDA granted Sarepta’s rAAVrh74 Viral Vector a Platform Technology Designation

June 5, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMTA, CYTK, SRPT, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$21.71 -0.03 (-0.14%)

Closing price 04:00 PM Eastern

Extended Trading

$21.68 -0.03 (-0.14%)

As of 04:06 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Clementia Pharmaceuticals NASDAQ:CMTA

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.

Cytokinetics NASDAQ:CYTK

$34.38 +1.18 (+3.55%)

Closing price 04:00 PM Eastern

Extended Trading

$34.00 -0.38 (-1.11%)

As of 04:22 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Sarepta Therapeutics NASDAQ:SRPT

$36.18 -1.13 (-3.03%)

Closing price 04:00 PM Eastern

Extended Trading

$36.25 +0.07 (+0.19%)

As of 04:35 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time